Pemberton, Hugh G. http://orcid.org/0000-0001-8419-6423
Goodkin, Olivia
Prados, Ferran
Das, Ravi K.
Vos, Sjoerd B.
Moggridge, James
Coath, William
Gordon, Elizabeth
Barrett, Ryan
Schmitt, Anne
Whiteley-Jones, Hefina
Burd, Christian
Wattjes, Mike P.
Haller, Sven
Vernooij, Meike W.
Harper, Lorna
Fox, Nick C.
Paterson, Ross W.
Schott, Jonathan M.
Bisdas, Sotirios
White, Mark
Ourselin, Sebastien
Thornton, John S.
Yousry, Tarek A.
Cardoso, M. Jorge
Barkhof, Frederik
,
Funding for this research was provided by:
University College London
Article History
Received: 29 April 2020
Revised: 1 October 2020
Accepted: 2 November 2020
First Online: 15 January 2021
Compliance with ethical standards
:
: The scientific guarantor of this publication is Prof Frederik Barkhof.
: SH is a speaker for General Electric, a consultant for Spineart and on the imaging advisory board for the European Prevention of Alzheimer’s Disease. JC and SO are founders of Brainminer. MPW received speaker and/or consultancy fees from Bayer, Biogen, Biologix, Celgene, GeniLac, Imcyse, Medison, Merck-Serono, Novartis, Sanofi Genzyme, and Roche. FB is a board member for Neurology, Brain, Radiology, and MSJ; section editor for Neuroradiology; personal fees from Bayer, Biogen, Roche, IXICO, and GeNeuro; grants from Novartis, Teva Pharmaceuticals, Merck, Biogen, Innovative Medicines Initiative, General Electric Healthcare, UK MS Society, Dutch Foundation MS Research, NWO, and NIHR. JMS has received research funding and PET tracer from AVID Radiopharmaceuticals (a wholly owned subsidiary of Eli Lilly); has consulted for Roche, Eli Lilly, Biogen, Merck, and GE; received royalties from Oxford University Press and Henry Stewart Talks; given education lectures sponsored by Eli Lilly, Biogen, and GE; and served on a Data Safety Monitoring Committee for Axon Neuroscience SE. He is Chief Medical Officer for Alzheimer’s Research UK.
: One of the authors has significant statistical expertise.
: Written informed consent was obtained from all subjects and patients in this study.
: Subject data in the ‘reference dataset’ were acquired under the ethical agreements in place for ADNI and TRACK-HD studies. All subjects in the ‘patient dataset’ gave their informed consent for all parts of the study under research ethical approval by the Queen Square ethics committee: References: 13 LO 0005 and 12 LO 1504.
: Some study subjects or cohorts have been previously reported in:Tabrizi SJ, Reilmann R, Roos RA, et al (2012) Potential endpoints for clinical trials in premanifest and early Huntington’s disease in the TRACK-HD study: analysis of 24 month observational data. <i>Lancet Neurol</i> 11:42–53.Studies related to the Alzheimer’s Disease Neuroimaging Initiative
: • retrospective• cross-sectional study/diagnostic• multicentre study